Streetbeat News

Price Targets

HUMA

Benchmark analyst Bruce Jackson has reiterated a Buy rating on Humacyte (NASDAQ:HUMA) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:33 pm

CABA

UBS has initiated coverage on Cabaletta Bio with a Buy rating and set a price target of $10, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:31 pm

META

Truist Securities has maintained its Buy rating on Meta Platforms and increased the price target from $570 to $650, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:23 pm

LLY

Truist Securities has maintained its Buy rating on Eli Lilly and raised the price target from $1000 to $1033, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:22 pm

BP

Scotiabank analyst Paul Cheng has downgraded BP from Sector Outperform to Sector Perform and reduced the price target from $42 to $36.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:21 pm

GDTC

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on CytoMed Therapeutics (NASDAQ:GDTC) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:19 pm

ABBV

Truist Securities has maintained its Buy rating on AbbVie and increased the price target from $210 to $215, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:17 pm

CRTO

Benchmark analyst Mark Zgutowicz has reiterated a Buy rating on Criteo (NASDAQ:CRTO) and maintained a price target of $56.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:14 pm

HUBB

JP Morgan analyst Stephen Tusa has downgraded Hubbell from Overweight to Neutral while raising the price target from $385 to $454.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:13 pm

BMRN

Raymond James analyst Danielle Brill has reinstated an Outperform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) with a price target of $79.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:10 pm